一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国结直肠癌领域Poster Session共入选17项。期待中国专家在ASCO年会上展现风采！

胃肠道肿瘤-结直肠与肛门

Gastrointestinal Cancer—Colorectal and Anal

01

摘要号：3543

标题：A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.

报告人：许婷

单位：北京大学肿瘤医院

02

摘要号：3547

标题：A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.

报告人：Lei Xiao

单位：斯丹赛(上海)生物医药技术有限公司

03

摘要号：3555

标题：A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.

报告人：李晟

单位：江苏省肿瘤医院

04

摘要号：3559

标题：Novel GUCY2C targeting CAR-T therapy: Efficacy in advanced colorectal cancer.

报告人：Qianyu Zhang

单位：安徽省肿瘤医院

05

摘要号：3562

标题：A phase II study of regorafenib plus sintilimab as salvage-line treatments in non–MSI-H metastatic colorectal cancer (mCRC).

报告人：刘锐

单位：天津医科大学肿瘤医院

06

摘要号：3563

标题：Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.

报告人：阮丹云

单位：中山大学肿瘤防治中心

07

摘要号：3581

标题：Deep learning-derived spatial organization features on histopathology images to predict prognosis in patients with colorectal liver metastasis, after hepatectomy.

报告人：王鑫

单位：香港中文大学

08

摘要号：3582

标题：Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

报告人：赵文思

单位：武汉大学人民医院

09

摘要号：3585

标题：Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases.

报告人：Aiwei Feng

单位：北京大学肿瘤医院

10

摘要号：3586

标题：Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.

报告人：袁瑛

单位：浙江大学医学院附属第二医院

11

摘要号：3596

标题：VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.

报告人：Yijiao Chen

单位：复旦大学附属中山医院

12

摘要号：3611

标题：The role of image-guided volume-adapted high-dose-rate endorectal brachytherapy boost in total neoadjuvant treatment of distal locally advanced rectal cancer.

报告人：Huangang Jiang

单位：武汉大学中南医院

13

摘要号：3613

标题：Efficacy and safety of mFOLFOX6 with apatinib as postoperative adjuvant chemotherapy in stage IIIB or IIIC colorectal cancer.

报告人：顾晓冬

单位：复旦大学附属华山医院

14

摘要号：3619

标题：Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: Can it improve the oncologic prognosis?

报告人：孙立峰

单位：浙江大学医学院附属第二医院

15

摘要号：3621

标题：Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.

报告人：龚继芳

单位：北京大学肿瘤医院

16

摘要号：TPS3637

标题：PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer.

报告人：Zhenlin Hou

单位：中山大学肿瘤防治中心

17

摘要号：TPS3638

标题：Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (union ).

报告人：林振宇

单位：华中科技大学同济医学院附属协和医院

备注：排名不分先后，按照摘要号进行

如有遗漏或任何问题，请给我们留言~